Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ:BMRN) on Friday, setting a price target of $141, which is approximately 68.04% above the present share price of $83.91.
Moussatos expects BioMarin Pharmaceutical to post earnings per share (EPS) of $0.10 for the third quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in BioMarin Pharmaceutical, with an average price target of $107.09.
The analysts price targets range from a high of $141 to a low of $82.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $486.07 million and a net profit of $27.48 million. The company's market cap is $15.33 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.5% and a 42.46% success rate.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.